CD274 and neoplasm: At the same time, in the existing immunotherapy cohorts analysis, we found that GSDMB also has significant value as a biomarker to predict the efficacy of immunotherapy, yielding better performance than microsatellite instability (MSI), PD‐L1, tumor mutational burden (TMB), and other classic prediction indicators (Figure S12–S14, Supporting Information).